KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) Net Margin (2019 - 2025)

Esperion Therapeutics' Net Margin history spans 7 years, with the latest figure at 37.16% for Q4 2025.

  • For Q4 2025, Net Margin rose 7923.0% year-over-year to 37.16%; the TTM value through Dec 2025 reached 6.04%, down 210.0%, while the annual FY2025 figure was 5.62%, 995.0% up from the prior year.
  • Net Margin reached 37.16% in Q4 2025 per ESPR's latest filing, up from 36.66% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 42.29% in Q1 2024 to a low of 1140.0% in Q1 2021.
  • Average Net Margin over 5 years is 217.35%, with a median of 151.63% recorded in 2023.
  • Peak YoY movement for Net Margin: surged 313267bps in 2021, then crashed -24628bps in 2022.
  • A 5-year view of Net Margin shows it stood at 448.4% in 2021, then skyrocketed by 33bps to 302.06% in 2022, then soared by 41bps to 178.06% in 2023, then soared by 76bps to 42.07% in 2024, then soared by 188bps to 37.16% in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Net Margin are 37.16% (Q4 2025), 36.66% (Q3 2025), and 16.25% (Q2 2025).